Intrahepatic Cholangiocarcinoma Adjacent Tissue Proteomics for Recurrence Prediction

A proteomic analysis of 116 adjacent-to-tumor tissue samples from intrahepatic cholangiocarcinoma patients, used to construct a postoperative recurrence prediction model. The study identified two molecular subtypes and a four-molecule signature (ENO3, HSPA13, POSTN, PTBP3) for risk stratification, with validation performed on an independent cohort of 88 samples.

Use Cases

• Train a Cox regression model using the four-molecule signature (ENO3, HSPA13, POSTN, PTBP3) to predict patient recurrence risk.
• Classify iCCA adjacent tissues into S1 and S2 subtypes based on proteomic profiles to analyze differences in recurrence rates and immune scores.
• Validate the expression and prognostic value of the POSTN protein as an independent factor for recurrence using immunohistochemistry data from an 88-sample cohort.
• Analyze correlations between the high-risk recurrence group and predicted responses to immunotherapy, chemotherapy, or targeted therapies.

Strengths

• Proteomic data from 116 iCCA patient samples provides a foundation for model development.
• Model validation uses an independent cohort of 88 iCCA tissue samples via tissue microarray and immunohistochemistry.
• The study delivers a specific four-molecule signature (ENO3, HSPA13, POSTN, PTBP3) with identified clinical associations.

Limitations

• The dataset is contained within a 10.9 MB PDF, requiring manual extraction of underlying tabular data for computational analysis.
• Sample size is limited to 116 patients for model construction, which may constrain statistical power for rare event prediction.
• Geographic and demographic details of the patient cohorts are not specified, potentially limiting generalizability.

Provenance

Source

Rongyu Ping via figshare.

Collection Method

Proteomic analysis of 116 iCCA adjacent-to-tumor tissues, with validation via tissue microarray and immunohistochemistry on an independent 88-sample cohort.

Freshness

Last updated March 2026.